📊 VNDA Key Takeaways
Is Vanda Pharmaceuticals Inc. (VNDA) a Good Investment?
Vanda Pharmaceuticals is a cash-burning pharmaceutical company with zero revenue growth, severe operating losses (-$97.1% margin), and unsustainable negative free cash flow (-$50.4M). Despite maintaining $54M in liquidity and no debt, the company's burn rate will deplete cash within 12 months at current trends. Without demonstrated revenue growth or a clear path to profitability, fundamental operations are critically impaired.
Vanda Pharmaceuticals Inc. Key Strengths (VNDA)
- Maintains adequate short-term liquidity with $54M cash and 2.16x current ratio
- Zero long-term debt (0.00x debt-to-equity) reduces near-term refinancing pressure
- Operates in pharmaceutical sector with potential upside if pipeline products achieve regulatory approval
VNDA Stock Risks: Vanda Pharmaceuticals Inc. Investment Risks
- Unsustainable cash burn: -$50.4M free cash flow against only $54M cash implies <12 month runway at current burn rate
- Complete operational failure: -$50.2M operating loss on $51.7M revenue with -97.1% operating margin
- Zero revenue growth (0.0% YoY) indicates stagnant demand, competitive displacement, or market rejection
Key Metrics to Watch
- Quarterly revenue trends and new product commercialization timelines
- Operating cash flow trajectory and actual cash burn rate vs. projections
- Debt issuance or equity financing announcements indicating liquidity needs
Vanda Pharmaceuticals Inc. (VNDA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.16x current ratio provides a solid financial cushion.
VNDA Profit Margin, ROE & Profitability Analysis
VNDA vs Healthcare Sector: How Vanda Pharmaceuticals Inc. Compares
How Vanda Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vanda Pharmaceuticals Inc. Stock Overvalued? VNDA Valuation Analysis 2026
Based on fundamental analysis, Vanda Pharmaceuticals Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vanda Pharmaceuticals Inc. Balance Sheet: VNDA Debt, Cash & Liquidity
VNDA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vanda Pharmaceuticals Inc.'s revenue has declined by 20% over the 5-year period, indicating business contraction. The most recent EPS of $0.04 reflects profitable operations.
VNDA Revenue Growth, EPS Growth & YoY Performance
VNDA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $50.0M | -$29.5M | $-0.50 |
| Q3 2025 | $47.7M | -$4.1M | $-0.09 |
| Q2 2025 | $50.5M | -$4.1M | $-0.08 |
| Q1 2025 | $47.5M | -$4.1M | $-0.07 |
| Q3 2024 | $38.8M | $137.0K | $0.00 |
| Q2 2024 | $46.1M | $1.5M | $0.03 |
| Q1 2024 | $47.5M | $3.3M | $0.06 |
| Q3 2023 | $38.8M | $137.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vanda Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
VNDA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vanda Pharmaceuticals Inc. (CIK: 0001347178)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VNDA
What is the AI rating for VNDA?
Vanda Pharmaceuticals Inc. (VNDA) has an AI grade of D with 82% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VNDA's key strengths?
Claude: Maintains adequate short-term liquidity with $54M cash and 2.16x current ratio. Zero long-term debt (0.00x debt-to-equity) reduces near-term refinancing pressure.
What are the risks of investing in VNDA?
Claude: Unsustainable cash burn: -$50.4M free cash flow against only $54M cash implies <12 month runway at current burn rate. Complete operational failure: -$50.2M operating loss on $51.7M revenue with -97.1% operating margin.
What is VNDA's revenue and growth?
Vanda Pharmaceuticals Inc. reported revenue of $51.7M.
Does VNDA pay dividends?
Vanda Pharmaceuticals Inc. does not currently pay dividends.
Where can I find VNDA SEC filings?
Official SEC filings for Vanda Pharmaceuticals Inc. (CIK: 0001347178) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VNDA's EPS?
Vanda Pharmaceuticals Inc. has a diluted EPS of $-0.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is VNDA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Vanda Pharmaceuticals Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is VNDA stock overvalued or undervalued?
Valuation metrics for VNDA: ROE of -17.3% (sector avg: 15%), net margin of -93.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is VNDA's AI grade for 2026?
Our dual AI analysis gives Vanda Pharmaceuticals Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VNDA's free cash flow?
Vanda Pharmaceuticals Inc.'s operating cash flow is $-50.2M, with capital expenditures of $221.0K. FCF margin is -97.5%.
How does VNDA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -93.9% (avg: 12%), ROE -17.3% (avg: 15%), current ratio 2.16 (avg: 2).